1. Home
  2. LGCB vs LIXT Comparison

LGCB vs LIXT Comparison

Compare LGCB & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGCB

Linkage Global Inc

HOLD

Current Price

$2.00

Market Cap

23.4M

Sector

N/A

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.21

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGCB
LIXT
Founded
2011
2005
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
25.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LGCB
LIXT
Price
$2.00
$4.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
58.9K
106.6K
Earning Date
07-03-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,993,265.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.80
N/A
52 Week Low
$1.22
$0.64
52 Week High
$6.83
$6.26

Technical Indicators

Market Signals
Indicator
LGCB
LIXT
Relative Strength Index (RSI) 51.41 52.59
Support Level $1.76 $3.50
Resistance Level $2.09 $4.31
Average True Range (ATR) 0.11 0.31
MACD -0.02 0.00
Stochastic Oscillator 45.54 83.16

Price Performance

Historical Comparison
LGCB
LIXT

About LGCB Linkage Global Inc

Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: